Comparison of Haemodynamic Effects of Nifedipine and Molsidomine in Patients with Coronary Artery Disease

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1989 Jan 1

PMID 2598982

Authors

M Kyriakidis

G Vyssoulis

P Sfikakis

C Kyriakidis

C Pitsavos

K Valsamis

V NOMIKOS

P Toutouzas

Affiliations

Soon will be listed here.

Abstract

The haemodynamic effects of oral nifedipine 20 mg and molsidomine 4 mg were compared in 24 patients with coronary artery disease. Molsidomine unlike nifedipine caused a significant fall in mean pulmonary artery pressure and left ventricular end-diastolic pressure. Both drugs caused a significant and comparable reduction in systolic and diastolic blood pressure. Although only nifedipine significantly reduced systemic vascular resistance the difference between the drugs was not significant. The heart rate was significantly increased by nifedipine but not by molsidomine. The ejection phase indices were all increased by molsidomine and the increment in the mean normalized systolic ejection rate was significantly greater than that due to nifedipine. The left ventricular end-systolic volume index decreased significantly after molsidomine but not nifedipine. Neither drug significantly affected left ventricular end diastolic volume index, stroke volume index, maximal rate of rise of left ventricular pressure or left ventricular stroke work index.

References

Gerstenblith G, Ouyang P, Achuff S, Bulkley B, Becker L, Mellits E . Nifedipine in unstable angina: a double-blind, randomized trial. N Engl J Med. 1982; 306(15):885-9. DOI: 10.1056/NEJM198204153061501. View

FELDMAN R, Hill J, Conti J, Conti C, Pepine C . Analysis of coronary responses to nifedipine alone and in combination with intracoronary nitroglycerin in patients with coronary artery disease. Am Heart J. 1983; 105(4):651-8. DOI: 10.1016/0002-8703(83)90490-8. View

Matsumoto S, Ito T, Sada T, Takahashi M, Su K, Ueda A . Hemodynamic effects of nifedipine in congestive heart failure. Am J Cardiol. 1980; 46(3):476-80. DOI: 10.1016/0002-9149(80)90018-1. View

Antman E, Muller J, Goldberg S, MACALPIN R, Rubenfire M, TABATZNIK B . Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med. 1980; 302(23):1269-73. DOI: 10.1056/NEJM198006053022301. View

Packer M, Meller J, Medina N, Yushak M, Gorlin R . Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy. Am J Cardiol. 1981; 48(5):939-46. DOI: 10.1016/0002-9149(81)90362-3. View

Schanzenbacher P, Deeg P, LIEBAU G, Kochsiek K . Paradoxical angina after nifedipine: angiographic documentation. Am J Cardiol. 1984; 53(2):345-6. DOI: 10.1016/0002-9149(84)90458-2. View

Guerchicoff S, Vazquez A, Kunik H, Drajer S, Diaz F . Acute double blind trial of a new anti-anginal drug: molsidomine. Eur J Clin Pharmacol. 1978; 13(4):247-50. DOI: 10.1007/BF00716358. View

Elkayam U, Weber L, McKay C, Rahimtoola S . Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure. Am J Cardiol. 1984; 54(1):126-31. DOI: 10.1016/0002-9149(84)90316-3. View

Ludbrook P, Tiefenbrunn A, Reed F, Sobel B . Acute hemodynamic responses to sublingual nifedipine: dependence on left ventricular function. Circulation. 1982; 65(3):489-98. DOI: 10.1161/01.cir.65.3.489. View

10.

Elkayam U, Weber L, Torkan B, McKay C, Rahimtoola S . Comparison of hemodynamic responses to nifedipine and nitroprusside in severe chronic congestive heart failure. Am J Cardiol. 1984; 53(9):1321-5. DOI: 10.1016/0002-9149(84)90087-0. View

11.

Kukovetz W, Holzmann S, Wurm A, Poch G . Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1979; 310(2):129-38. DOI: 10.1007/BF00500277. View

12.

Brooks N, Cattell M, PIDGEON J, Balcon R . Unpredictable response to nifedipine in severe cardiac failure. Br Med J. 1980; 281(6251):1324. PMC: 1714741. DOI: 10.1136/bmj.281.6251.1324. View

13.

Kukovetz W, Holzmann S . Mechanism of vasodilation by molsidomine. Am Heart J. 1985; 109(3 Pt 2):637-40. DOI: 10.1016/0002-8703(85)90669-6. View

14.

Schulz W, Kober G, Bernauer R, Kaltenbach M . Active and passive changes in coronary diameter after vasodilation with SIN-1, the active metabolite of molsidomine. Am Heart J. 1985; 109(3 Pt 2):694-9. DOI: 10.1016/0002-8703(85)90685-4. View

15.

Gillmer D, Kark P . Pulmonary oedema precipitated by nifedipine. Br Med J. 1980; 280(6229):1420-1. PMC: 1601735. DOI: 10.1136/bmj.280.6229.1420. View

16.

Acar J, Kulas A, Escudier B . Long-term clinical and hemodynamic results of molsidomine treatment in patients with refractory heart failure. Am Heart J. 1985; 109(3 Pt 2):685-7. DOI: 10.1016/0002-8703(85)90682-9. View

17.

Drajer S, Cercos H, Torres H, Vazquez A, Cohn J, Romero N . Haemodynamic effects of oral molsidomine in pump failure complicating myocardial infarction. Eur J Clin Pharmacol. 1984; 27(4):419-22. DOI: 10.1007/BF00549588. View

18.

Mueller H, Chahine R . Interim report of multicenter double-blind, placebo-controlled studies of nifedipine in chronic stable angina. Am J Med. 1981; 71(4):645-57. DOI: 10.1016/0002-9343(81)90229-1. View

19.

Stone P, Antman E, Muller J, Braunwald E . Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med. 1980; 93(6):886-904. DOI: 10.7326/0003-4819-93-6-886. View

20.

Dalla-Volta S, Scorzelli L, Razzolini R . Evaluation of the chronic antianginal effect of molsidomine. Am Heart J. 1985; 109(3 Pt 2):682-4. DOI: 10.1016/0002-8703(85)90681-7. View